Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells
IntroductionVismodegib (VDG), a Smoothened inhibitor approved for basal cell carcinoma, has potential for repurposing in other tumors in which Hedgehog (Hh) signaling contributes to malignancy. However, systemic VDG treatment is associated with relevant adverse effects, and its effective delivery to...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2026-06-01
|
| Seri Bilgileri: | Frontiers in Medical Technology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fmedt.2026.1826970/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|